A phase l and randomized phase ll trial of radium-223 dichloride, peposertib, and avelumab in advanced metastatic castrate-resistant prostate cancer (mCRPC): Phase l results. This is an ASCO Meeting ...

Actinium Pharmaceuticals, Inc. (NYSE American: ATNM) (Actinium or the Company), a pioneer in the development of targeted radiotherapies, today announced the upcoming presentation of three abstracts at ...

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings.

Shares in Actinium Pharmaceuticals have lost almost two-thirds of their value after the FDA asked for a second clinical trial before it would consider reviewing the company's Iomab-B radioligand ...

After more than six years, Actinium is recording the much sought-after crackles of clinical connection in a phase 3 trial of its radiotherapy in older patients with leukemia. The company reported that ...

Researchers grew crystals containing actinium and illuminated them with X-rays to learn how the radioactive metal binds with other elements. That information could help design better cancer treatments ...

The FDA has torpedoed Actinium Pharmaceuticals’ hopes of winning a blood cancer approval based on existing data. With the agency requesting an additional head-to-head randomized clinical trial, ...

NEW YORK (AP) — NEW YORK (AP) — Actinium Pharmaceuticals Inc. (ATNM) on Friday reported a loss of $5.5 million in its first quarter. The New York-based company said it had a loss of 18 cents per share ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...